African Journal of
Biochemistry and Molecular Biology Research

ISSN : 0000-0000

Index: Harvard, Boston, Sydney University, Dimensions, Lens, ResearchGet Scilit, Semantic, Google Scholar, Base etc

https://doi.org/10.58578/AJBMBR.v1i1.3473

Review: Neurochemical Aspects of Mental Health and Neurological Diseases

Isaac John Umaru[1], Nwofor Innocent[2], Kerenhappuch Isaac Umaru[3]

[1,2]Federal University Wukari, Taraba State, Nigeria

[3]Saint Monica University Higher Institute Buea, South West Cameroon, Cameroon

umaruisaac@gmail.com

Article Info:

Submitted:	Revised:	Accepted:	Published:
Jul 1, 2024	Jul 21, 2024	Jul 24, 2024	Jul 27, 2024

Abstract

Neurochemistry is the study of chemicals, including neurotransmitters, hormones, and other molecules, that influence the function and behavior of the nervous system. This field has evolved significantly since the early 20th century, driven by key discoveries and technological advancements such as Neurotransmitters and Mental Health, "Neurotransmitters like serotonin, dopamine, and norepinephrine are fundamental in regulating mood, cognition, and behavior. Disruptions in these systems are implicated in various psychiatric disorders". Also, Neurotransmitter Imbalances and Mental Disorders: this is the Alterations in neurotransmitter levels, such as serotonin and dopamine, are associated with the symptoms of depression and schizophrenia". Then the GABAergic dysfunction is linked to anxiety disorders, highlighting the role of inhibitory neurotransmission in mental health". As well as Role of Neurochemicals in Specific Disorders: where low serotonin levels are commonly found in individuals with depression, leading to the development of SSRIs as a treatment". The review also look into Schizophrenia which is associated with both hyperactivity and hypoactivity of dopamine pathways, which influences treatment strategies", as well as the Neurochemical Pathways and Mechanisms: The HPA axis plays a critical role in the stress response, and its dysregulation which is linked to mood disorders". Dopaminergic pathways, including the mesolimbic and nigrostriatal systems, are essential for reward and motor control" as well as the Neurotransmitter Receptors and Transporters, Serotonin receptors, such as 5-HT1A, are critical in mood regulation and are targeted by many antidepressants". The central point of disorder "Dopamine transporters are involved in the re-uptake of dopamine and are implicated in disorders like ADHD and addiction". Thus, Neuroinflammation and Mental Health: which Increased neuroinflammation is associated with depression, with elevated pro-inflammatory cytokines observed in affected individuals", "Microglia and their role in neuroinflammation and psychiatric disorders are all the key area of the research."

Keywords: Neurochemical, Aspects, Mental, Health, Neurological, Diseases

Introduction

Neurochemistry is the study of chemicals, including neurotransmitters, hormones, and other molecules, that influence the function and behavior of the nervous system. This field has evolved significantly since the early 20th century, driven by key discoveries and technological advancements. (Nestler el.,2002) The pioneering work of Otto Loewi in the 1920s, who identified acetylcholine as a neurotransmitter, marked a significant milestone. His experiments demonstrated the chemical basis of synaptic transmission, a concept further expanded by the identification of other neurotransmitters like dopamine, serotonin, and norepinephrine.

The advent of advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry, in the mid-20th century, allowed for precise identification and quantification of neurochemicals. These methods facilitated deeper insights into the roles of these chemicals in both normal brain function and pathology. Molecular biology and genetics have further propelled the field, enabling the exploration of neurochemical pathways and their genetic regulation. (müller et al.,2015).

Key Neurochemicals and Their Roles

Neurochemicals include neurotransmitters, hormones, and other signaling molecules that regulate brain function. Neurotransmitters, the primary messengers of the nervous system, can be broadly categorized into excitatory and inhibitory types:

Excitatory Neurotransmitters: Glutamate, the most abundant excitatory neurotransmitter, is crucial for synaptic plasticity, learning, and memory. Its receptors, including NMDA, AMPA, and kainate receptors, facilitate fast synaptic transmission. However, excessive glutamate activity can lead to excitotoxicity, damaging neurons and contributing to conditions like Alzheimer's disease and stroke.

Inhibitory Neurotransmitters: GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter, reducing neuronal excitability and preventing overstimulation. GABAergic inhibition is vital for maintaining the balance of neural circuits. Dysregulation of GABAergic transmission is linked to anxiety disorders, epilepsy, and schizophrenia.

Hormones and Brain Function

Hormones, chemical messengers released by endocrine glands, also play significant roles in brain function. Key hormones influencing the brain include:

Cortisol: Known as the "stress hormone," cortisol is produced by the adrenal glands in response to stress. It helps regulate metabolism, immune response, and circadian rhythms. Chronic elevation of cortisol, often due to prolonged stress, can impair cognitive function and contribute to mood disorders such as depression and anxiety.

Oxytocin: Often referred to as the "love hormone," oxytocin is produced in the hypothalamus and released by the pituitary gland. It plays a crucial role in social bonding, trust, and emotional regulation. Research suggests oxytocin may have therapeutic potential for conditions like autism and social anxiety.

Melatonin: Produced by the pineal gland, melatonin regulates sleep-wake cycles and circadian rhythms. It influences sleep patterns and has neuroprotective properties, contributing to brain health.

Technological Advancements

Technological advancements have significantly advanced our understanding of neurochemical processes. Imaging techniques such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) enable visualization of neurochemical activity in real-time, providing insights into how neurotransmitters and hormones influence brain function and behavior. Electrophysiological techniques, such as patch-clamp recordings, allow the measurement of ion channel activity and synaptic transmission at high resolution, revealing the dynamics of neurochemical signaling.

Physiological Processes and Behaviors

Neurochemicals regulate various physiological processes and behaviors. For example:

Dopamine: Produced in the substantia nigra and ventral tegmental area, dopamine is critical for reward processing, motivation, and motor control. Dysregulation of dopamine pathways is implicated in conditions such as Parkinson's disease, schizophrenia, and addiction.

Serotonin: Synthesized from the amino acid tryptophan, serotonin regulates mood, anxiety, appetite, and sleep. Serotonergic dysfunction is associated with depression, anxiety disorders, and obsessive-compulsive disorder (OCD).

Acetylcholine: Involved in learning, memory, and attention, acetylcholine is produced by cholinergic neurons in the basal forebrain. Degeneration of these neurons is a hallmark of Alzheimer’s disease, leading to cognitive decline.

Understanding the roles of neurochemicals in physiological processes and behaviors is crucial for developing targeted interventions for mental health disorders and neurological diseases.

Importance of Neurochemistry in Mental Health

Neurotransmitters and Mental Health

Neurotransmitters play a pivotal role in regulating mood, cognition, and behavior. Dysregulation of these chemicals is often implicated in mental health disorders. Key neurotransmitters involved in mental health include:

1. Serotonin:

Function: Serotonin is synthesized from tryptophan and is found in the brain, intestines, and blood platelets. It regulates mood, anxiety, and happiness. Serotonin receptors are widesprea he brain, particularly in regions involved in emotional regulation.

Mental Health Implications: Low serotonin levels are linked to depression, anxiety, and OCD. SSRIs (Selective Serotonin Reuptake Inhibitors) increase serotonin levels and are commonly prescribed for these conditions. Research also suggests serotonin's role in neuroplasticity, influencing the brain's ability to adapt and change. (Berger et al.,2009)

2. Dopamine:

Function: Dopamine is produced in the substantia nigra and ventral tegmental area. It plays a key role in reward, motivation, and motor control. Dopaminergic pathways, including the mesolimbic and mesocortical pathways, are crucial for these functions. (Volkow et al.,2019)

Mental Health Implications: Dysregulation of dopamine pathways is associated with schizophrenia, bipolar disorder, and addiction. Schizophrenia, for instance, involves hyperactive dopamine transmission in the mesolimbic pathway, leading to symptoms like hallucinations and delusions. Dopamine-modulating drugs are used to manage these symptoms.

3. Norepinephrine:

Function: Norepinephrine is involved in the body's fight-or-flight response, affecting arousal and alertness. It is produced from dopamine in the adrenal medulla and certain brain regions.

Mental Health Implications: Imbalances in norepinephrine are linked to mood disorders. Elevated levels can contribute to anxiety, while reduced levels are associated with depression. SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) enhance the availability of norepinephrine and serotonin, used in treating depression and anxiety.

4. GABA and Glutamate:

Function: GABA reduces neuronal excitability, promoting relaxation and reducing anxiety, while glutamate is critical for synaptic plasticity and memory formation. GABAergic and glutamatergic systems must be balanced for optimal brain function. (kandel et al.,2013)

Mental Health Implications: An imbalance between GABA and glutamate can lead to disorders like anxiety, epilepsy, and neurodegenerative diseases. Increased glutamate activity can cause excitotoxicity, contributing to conditions like Alzheimer's. Benzodiazepines, which enhance GABA activity, are used to treat anxiety and seizures.(Carlsson & Lindqvist, 1963).

Hormones and Mental Health

Hormones also significantly impact mental health by modulating brain function and behavior. Key hormones involved include:

1. Cortisol:

Function: Cortisol is released in response to stress and regulates various bodily functions, including metabolism and immune response. The hypothalamic-pituitary-adrenal (HPA) axis controls cortisol production. (Pariante & Lighman, 2008)

Mental Health Implications: Chronic stress and elevated cortisol levels are associated with anxiety and depression. Prolonged exposure to high cortisol can impair cognitive functions and contribute to mood disorders. Stress management techniques and medications targeting the HPA axis are used to modulate cortisol levels.

2. Oxytocin:

Function: Oxytocin is produced in the hypothalamus and released by the pituitary gland. It influences social bonding, trust, and emotional regulation. Oxytocin receptors are found in brain regions involved in social behavior and stress response.

Mental Health Implications: Oxytocin is being studied for its potential in treating conditions like autism and social anxiety. It promotes social interactions and reduces fear in social contexts, offering potential therapeutic benefits for enhancing social functioning. (Carter,1998)

Implications for Treatment

Understanding the neurochemical basis of mental health disorders has led to the development of targeted pharmacological interventions. For instance, antidepressants like SSRIs and SNRIs, antipsychotics, and anxiolytics aim to restore the balance of neurotransmitters. Emerging treatments, such as neuromodulation techniques (e.g., transcranial magnetic stimulation and deep brain stimulation), directly influence neurochemical activity, offering new avenues for treating refractory mental health conditions.

Research into the genetic and environmental factors affecting neurochemistry can lead to personalized medicine approaches, improving therapeutic outcomes and minimizing side effects by tailoring treatments to individual neurochemical profiles. (Heinrichs et at., 2016)

Significance of Neurochemistry in Neurological Diseases

Neurodegenerative Diseases

Neurodegenerative diseases involve the progressive loss of structure or function of neurons, including their death. Neurochemical alterations play a central role in the pathophysiology of these diseases. Two prominent examples include Alzheimer's disease and Parkinson's disease.

1. Alzheimer's Disease:

Neurochemical Basis: Alzheimer's disease (AD) is characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. These pathological features disrupt neuronal communication and lead to neuronal death. A significant reduction in acetylcholine, a neurotransmitter crucial for learning and memory, is observed due to the degeneration of cholinergic neurons in the basal forebrain. This depletion is closely associated with cognitive decline and memory loss.

Therapeutic Approaches: Current treatments for AD primarily aim to manage symptoms rather than cure the disease. Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, increase acetylcholine levels by inhibiting its breakdown, thereby improving cognitive function and slowing symptom progression. Another drug, memantine, an NMDA receptor antagonist, helps regulate glutamate activity to prevent excitotoxicity, which can further damage neurons. Ongoing research is exploring disease-modifying therapies targeting amyloid-beta and tau proteins.

2.Parkinson's Disease:

Neurochemical Basis: Parkinson's disease (PD) primarily results from the degeneration of dopaminergic neurons in the substantia nigra, a brain region crucial for motor control. This degeneration leads to a significant reduction in dopamine levels, causing the hallmark motor symptoms of PD, including tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Other neurochemical changes, such as alterations in serotonin and norepinephrine levels, also contribute to the non-motor symptoms of PD, including depression, anxiety, and cognitive impairment.

Therapeutic Approaches: Treatment strategies for PD focus on restoring dopamine levels and improving motor function. Levodopa, the precursor to dopamine, remains the most effective treatment. It is often combined with carbidopa, which prevents levodopa's breakdown before it reaches the brain. Dopamine agonists, such as pramipexole and ropinirole, mimic dopamine's effects, while MAO-B inhibitors, like selegiline and rasagiline, reduce dopamine breakdown. Deep brain stimulation (DBS), a surgical intervention, involves implanting electrodes in specific brain areas to modulate abnormal neural activity, providing significant symptom relief for some patients.

Other Neurological Diseases

1. Huntington's Disease:

Neurochemical Basis: Huntington's disease (HD) is a genetic disorder caused by a mutation in the huntingtin gene, leading to the production of an abnormal protein. This protein accumulation results in the degeneration of GABAergic neurons in the basal ganglia, leading to a decrease in inhibitory neurotransmission and an imbalance between excitatory and inhibitory pathways. This imbalance contributes to the motor, cognitive, and psychiatric symptoms of HD.

Therapeutic Approaches: There is currently no cure for HD, and treatments primarily focus on symptom management. Antipsychotic drugs, such as haloperidol, can help control chorea (involuntary movements), while antidepressants and mood stabilizers address psychiatric symptoms. Research into gene-silencing techniques, such as antisense oligonucleotides, holds promise for future disease-modifying treatments.

2. Amyotrophic Lateral Sclerosis (ALS):

Neurochemical Basis: ALS, also known as Lou Gehrig's disease, involves the progressive degeneration of motor neurons, leading to muscle weakness and atrophy. Excitotoxicity, primarily mediated by excessive glutamate activity, is a key neurochemical mechanism contributing to motor neuron death in ALS. Abnormalities in other neurotransmitters, such as GABA and acetylcholine, also play roles in the disease's progression.

Therapeutic Approaches: Riluzole, a drug that reduces glutamate release, is one of the few approved treatments for ALS and can modestly extend survival. Another drug, edaravone, has antioxidant properties and can slow disease progression in some patients. Ongoing research aims to identify new therapeutic targets to protect motor neurons and improve patient outcomes.

Neurochemical Basis of Depression

Depression, a pervasive and debilitating mental health disorder, is characterized by persistent sadness, loss of interest or pleasure in most activities, and various cognitive and physical symptoms. Affecting millions of people worldwide, depression significantly impairs daily functioning and quality of life. Understanding its neurochemical basis is crucial for developing effective treatments. Central to the pathology of depression are imbalances in several key neurotransmitters, neuroinflammatory processes, and changes in neuroplasticity.

Neurotransmitters in Depression

1. Serotonin (5-HT):

- Role and Function: Serotonin, synthesized from the amino acid tryptophan, plays a pivotal role in regulating mood, appetite, sleep, and cognition. Serotonergic neurons primarily located in the raphe nuclei of the brainstem project widely to various brain regions, including the limbic system and prefrontal cortex, which are crucial for mood regulation. (Savitz et al.,2009)
- Imbalance and Impact: Reduced serotonin levels and impaired serotonin receptor function are strongly associated with depression. Low serotonin availability in the synaptic cleft can result from decreased synthesis, increased reuptake, or receptor dysfunction. These deficits contribute to depressive symptoms, such as low mood, anxiety, and sleep disturbances.
- Therapeutic Approaches: Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, sertraline, and citalopram are commonly prescribed antidepressants that work by inhibiting the reuptake of serotonin, thereby increasing its availability in the synaptic cleft. Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as

venlafaxine and duloxetine, target both serotonin and norepinephrine reuptake, addressing multiple neurotransmitter imbalances. (Meyer & Quenzer, 2005)

2. Norepinephrine (NE):

- Role and Function: Norepinephrine, synthesized from dopamine, is involved in regulating arousal, alertness, and the stress response. Noradrenergic neurons are primarily located in the locus coeruleus and project to various brain regions, including the prefrontal cortex and limbic system. (Eisenberg et al., 2014)
- Imbalance and Impact: Alterations in norepinephrine levels and receptor function are associated with depression. Low norepinephrine availability can result from decreased synthesis or increased reuptake, contributing to symptoms such as fatigue, lack of concentration, and anhedonia (loss of pleasure). (Arnold et al., 2006)
- Therapeutic Approaches: SNRIs, which inhibit the reuptake of both serotonin and norepinephrine, are effective in treating depression by increasing the availability of these neurotransmitters. Tricyclic antidepressants (TCAs) like amitriptyline and nortriptyline also target norepinephrine reuptake and are used for more severe or treatment-resistant depression.

3. Dopamine (DA):

- Role and Function: Dopamine, synthesized from the amino acid tyrosine, plays a crucial role in reward processing, motivation, and cognitive function. Dopaminergic neurons are located in the substantia nigra and ventral tegmental area, projecting to regions like the prefrontal cortex and striatum.
- Imbalance and Impact: Dysregulation of dopamine pathways, particularly reduced dopamine transmission in the mesolimbic and mesocortical pathways, is implicated in depression. Low dopamine levels can lead to anhedonia, lack of motivation, and cognitive impairments.
- Therapeutic Approaches: Atypical antipsychotics, such as aripiprazole and quetiapine, can enhance dopamine transmission and are sometimes used as adjuncts to antidepressants in treatment-resistant depression. Bupropion, a norepinephrine-dopamine reuptake inhibitor (NDRI), directly increases dopamine and

norepinephrine levels and is effective for certain patients. (Carlsson & Lindqvist, 1963).

Neuroinflammation and Depression

Emerging research highlights the role of neuroinflammation in depression. Chronic stress and other factors can activate the immune system, leading to the release of pro-inflammatory cytokines that impact brain function.

Mechanisms: Pro-inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), can alter neurotransmitter metabolism, reduce neurogenesis, and disrupt synaptic plasticity. These changes contribute to the development and persistence of depressive symptoms.

Therapeutic Approaches: Anti-inflammatory treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and cytokine inhibitors, are being investigated for their potential to alleviate depression by reducing neuroinflammation. Omega-3 fatty acids, which have anti-inflammatory properties, are also explored as adjunctive treatments.

Neuroplasticity and Depression

Depression is associated with impairments in neuroplasticity, the brain's ability to adapt and reorganize in response to experiences and environmental changes.

Neurochemical Basis of Schizophrenia

Schizophrenia is a chronic and severe mental disorder affecting how a person thinks, feels, and behaves. Characterized by symptoms such as hallucinations, delusions, disorganized thinking, and cognitive impairments, schizophrenia profoundly impacts daily functioning and quality of life. The exact causes of schizophrenia are not fully understood, but neurochemical imbalances play a significant role in its pathology. Key neurotransmitters involved include dopamine, glutamate, and serotonin.

Key Neurotransmitters in Schizophrenia

1. Dopamine (DA):

- Role and Function: Dopamine is central to the brain's reward and motivation systems. It is synthesized from the amino acid tyrosine and is involved in regulating mood, cognition, and motor control. Dopaminergic neurons, located primarily in the substantia nigra and ventral tegmental area, project to various brain regions, including the prefrontal cortex and limbic system.
- imbalance and Impact: The dopamine hypothesis of schizophrenia suggests that hyperactivity in dopaminergic pathways, particularly the mesolimbic pathway, contributes to positive symptoms such as hallucinations and delusions. Conversely, hypoactivity in the mesocortical pathway is thought to contribute to negative symptoms and cognitive deficits. Increased dopamine synthesis, release, and receptor sensitivity have been implicated in the pathophysiology of schizophrenia.
- Therapeutic Approaches: Antipsychotic medications, including first-generation (typical) antipsychotics like haloperidol and second-generation (atypical) antipsychotics like risperidone and clozapine, target dopamine receptors to reduce symptoms. Typical antipsychotics primarily block D2 dopamine receptors, effectively reducing positive symptoms but often causing side effects such as tardive dyskinesia. Atypical antipsychotics have a broader mechanism of action, targeting both dopamine and serotonin receptors, and are associated with fewer motor side effects.

2. Glutamate:

- Role and Function: Glutamate is the main excitatory neurotransmitter in the brain, playing a crucial role in synaptic plasticity, learning, and memory. It acts on various receptors, including NMDA, AMPA, and kainate receptors.
- Imbalance and Impact: The glutamate hypothesis of schizophrenia posits that hypofunction of NMDA receptors, particularly in the prefrontal cortex and hippocampus, contributes to the disorder. NMDA receptor hypofunction can lead to decreased inhibition of dopamine neurons, resulting in dopaminergic

hyperactivity. This imbalance may contribute to both positive and negative symptoms as well as cognitive deficits.

- Therapeutic Approaches: Current antipsychotic treatments primarily target dopamine pathways, but there is growing interest in developing glutamate-based therapies. Agents that enhance NMDA receptor function, such as glycine and D-serine, have shown promise in alleviating symptoms. Additionally, research is exploring the potential of metabotropic glutamate receptor (mGluR) modulators in treating schizophrenia.

3. Serotonin (5-HT):

- Role and Function: Serotonin is involved in regulating mood, cognition, and perception. Serotonergic neurons in the raphe nuclei project to various brain regions, including the prefrontal cortex and limbic system.
- Imbalance and Impact: Alterations in serotonin levels and receptor function are implicated in schizophrenia. The interaction between serotonin and dopamine systems is complex, with serotonin modulating dopamine activity in various brain regions. Dysregulation of serotonin pathways can contribute to both positive and negative symptoms as well as cognitive impairments.
- Therapeutic Approaches: Atypical antipsychotics target both dopamine and serotonin receptors, providing a more balanced approach to treatment. These medications, such as clozapine and olanzapine, often have a higher affinity for serotonin receptors (e.g., 5-HT2A receptors) than for dopamine receptors, which helps in reducing symptoms and minimizing side effects. The development of novel serotonergic agents, including 5-HT2A receptor antagonists, is an active area of research.

Neurocircuitry and Schizophrenia

- Schizophrenia involves dysregulation in multiple neural circuits, including those connecting the prefrontal cortex, hippocampus, thalamus, and striatum.
- Prefrontal Cortex: The prefrontal cortex is crucial for executive functions, decision-making, and working memory. Dysfunction in this region, characterized by reduced

activity and connectivity, is associated with negative symptoms and cognitive deficits.

- Hippocampus: The hippocampus plays a vital role in memory formation and contextual processing. Structural and functional abnormalities in the hippocampus are linked to cognitive impairments and disorganized thinking in schizophrenia.
- Thalamus: The thalamus acts as a relay station for sensory and motor signals. Altered thalamic function and connectivity with cortical and subcortical regions are implicated in sensory processing deficits and cognitive disturbances.
- Striatum: The striatum is involved in motor control and reward processing. Hyperactivity in the striatal dopamine system is associated with positive symptoms such as hallucinations and delusions.

Mechanisms: Chronic stress and depression can reduce the expression of brain-derived neurotrophic factor (BDNF), a protein that supports neuronal survival, growth, and synaptic plasticity. Decreased BDNF levels are linked to atrophy in brain regions like the hippocampus, which is involved in mood regulation and memory.

Therapeutic Approaches: Antidepressants, particularly SSRIs and SNRIs, can enhance neuroplasticity by increasing BDNF levels. Other interventions, such as physical exercise, cognitive-behavioral therapy (CBT), and electroconvulsive therapy (ECT), also promote neuroplasticity and improve depressive symptoms.

Neurochemical Basis of Anxiety Disorders

Anxiety disorders represent a spectrum of mental health conditions characterized by excessive fear, worry, and related behavioral disturbances. This category includes generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and specific phobias. A deeper understanding of the neurochemical imbalances involved in anxiety disorders is essential for developing effective treatments and interventions.

Neurotransmitters in Anxiety Disorders

1. Gamma-Aminobutyric Acid (GABA):

- Role and Function: GABA is the primary inhibitory neurotransmitter in the brain, playing a crucial role in reducing neuronal excitability and promoting relaxation. GABAergic neurons are widely distributed across the brain, helping to maintain a balance between excitation and inhibition necessary for normal brain function.
- Imbalance and Impact: In anxiety disorders, GABAergic transmission is often reduced. Low levels of GABA or dysfunctional GABA receptors can lead to excessive neuronal activity, contributing to symptoms such as hypervigilance, restlessness, and panic attacks. This imbalance can result in an inability to effectively manage stress and anxiety.
- Therapeutic Approaches: Benzodiazepines, such as diazepam and lorazepam, are commonly prescribed to enhance GABAergic transmission by increasing GABA receptor activity, providing rapid relief from acute anxiety. However, due to the potential for dependence and tolerance, these medications are generally recommended for short-term use. Other medications, such as selective serotonin reuptake inhibitors (SSRIs), can indirectly enhance GABAergic function by increasing serotonin levels, offering a longer-term treatment option.

2.Serotonin (5-HT):

- Role and Function: Serotonin is a key neurotransmitter involved in the regulation of mood, anxiety, and fear responses. Serotonergic neurons, primarily located in the raphe nuclei of the brainstem, project to various brain regions, including the amygdala and prefrontal cortex, which are critical for anxiety regulation.
- Imbalance and Impact: Altered serotonin levels and receptor function are commonly observed in individuals with anxiety disorders. Low serotonin availability or dysfunctional serotonin receptors can exacerbate anxiety symptoms, leading to chronic worry and fear.
- Therapeutic Approaches: SSRIs, including fluoxetine, sertraline, and paroxetine, are considered first-line treatments for anxiety disorders. These medications work by inhibiting the reuptake of serotonin, thereby increasing its availability in the synaptic cleft and reducing anxiety symptoms. Serotonin-norepinephrine reuptake

inhibitors (SNRIs), such as venlafaxine and duloxetine, are also effective, targeting both serotonin and norepinephrine to alleviate anxiety.

3. Norepinephrine (NE):

- Role and Function: Norepinephrine is a neurotransmitter involved in the body's stress response, affecting arousal, alertness, and attention. Noradrenergic neurons located in the locus coeruleus project to brain regions implicated in anxiety, including the amygdala and hippocampus.
- Imbalance and Impact: Dysregulation of norepinephrine pathways, characterized by increased noradrenergic activity, is a hallmark of anxiety disorders. Elevated norepinephrine levels can lead to hyperarousal, increased heart rate, and other physical symptoms of anxiety.
- Therapeutic Approaches: Beta-blockers, such as propranolol, are used to reduce the physical symptoms of anxiety by blocking norepinephrine receptors, which decreases heart rate and blood pressure. Additionally, alpha-2 adrenergic agonists like clonidine can modulate norepinephrine release and are sometimes used to treat specific anxiety disorders.

Neurocircuitry and Anxiety Disorders

The neural circuits involved in anxiety disorders include the amygdala, prefrontal cortex, hippocampus, and brainstem. Dysregulation in these circuits contributes to the development and persistence of anxiety symptoms.

Amygdala: The amygdala is crucial for processing fear and threat-related stimuli. Hyperactivity in the amygdala is a common feature of anxiety disorders, leading to exaggerated fear responses and heightened anxiety.

Prefrontal Cortex: The prefrontal cortex is involved in the regulation of emotional responses and decision-making. Impaired connectivity between the prefrontal cortex and the amygdala can reduce the ability to modulate fear and anxiety effectively, resulting in heightened and persistent anxiety symptoms.

Hippocampus: The hippocampus is essential for forming new memories and contextualizing fear. In anxiety disorders, changes in hippocampal function can contribute to difficulties in distinguishing between safe and threatening situations, perpetuating anxiety.

Brainstem: The brainstem, particularly the locus coeruleus, is involved in the body's arousal and stress responses. Dysregulation in this area can lead to increased noradrenergic activity, contributing to the physical symptoms of anxiety such as increased heart rate and muscle tension.

Neurochemical Basis of Bipolar Disorder

Bipolar disorder, historically known as manic-depressive illness, is a complex mental health condition characterized by extreme mood swings, encompassing periods of manic or hypomanic episodes (elevated mood, increased energy, and activity levels) and depressive episodes (low mood, energy, and activity). These drastic mood fluctuations can severely impair an individual's daily functioning, interpersonal relationships, and overall quality of life. The pathophysiology of bipolar disorder is multifaceted, involving a combination of genetic, environmental, and neurochemical factors. Key neurotransmitters implicated in the neurochemical basis of bipolar disorder include serotonin, dopamine, and norepinephrine.

Key Neurotransmitters in Bipolar Disorder

1. Serotonin

Role and Function: Serotonin is a crucial neurotransmitter involved in the regulation of mood, sleep, appetite, and cognition. Synthesized from the amino acid tryptophan, serotonergic neurons are predominantly found in the raphe nuclei of the brainstem. These neurons project to various regions of the brain, including the prefrontal cortex, hippocampus, and limbic system, which are areas critical for mood regulation.

Imbalance and Impact: The dysregulation of serotonin pathways is a significant factor in both manic and depressive episodes of bipolar disorder. Low levels of serotonin or impaired serotonin receptor function are commonly associated with depressive symptoms, such as sadness, fatigue, and loss of interest in activities. During manic episodes, alterations in serotonin receptor sensitivity and signaling can contribute to heightened mood, increased activity, and impulsivity. The serotonergic system's involvement in mood stabilization indicates that maintaining balanced serotonin levels is essential for managing bipolar disorder effectively.

Therapeutic Approaches: Mood stabilizers like lithium and anticonvulsants (e.g., valproate and lamotrigine) are cornerstone treatments for bipolar disorder. These medications help stabilize serotonin levels and improve receptor function, thereby reducing the frequency and severity of mood episodes. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) may be used to treat depressive episodes, but they are often combined with mood stabilizers to prevent the induction of mania.

2. Norepinephrine (NE):

Role and Function: Norepinephrine, also known as noradrenaline, is a neurotransmitter involved in the body's stress response, arousal, and attention. Noradrenergic neurons are located in the locus coeruleus and project to various brain regions, including the prefrontal cortex, hippocampus, and amygdala.

Imbalance and Impact: Dysregulation of norepinephrine pathways is implicated in both manic and depressive phases of bipolar disorder. Increased norepinephrine activity is associated with manic symptoms such as hyperactivity, reduced need for sleep, heightened alertness, and irritability. During depressive episodes, decreased norepinephrine activity is linked to symptoms like fatigue, lack of concentration, and low mood. The balance of norepinephrine levels is crucial for maintaining mood stability in individuals with bipolar disorder.

Therapeutic Approaches: Mood stabilizers and atypical antipsychotics are commonly used to modulate norepinephrine activity and manage mood symptoms in bipolar disorder. While SNRIs increase norepinephrine levels, they must be used cautiously to avoid triggering manic episodes. Beta-blockers, which reduce norepinephrine activity, can be used to manage physical symptoms of mania, such as tachycardia and agitation.

Neurocircuitry and Bipolar Disorder

The neural circuitry involved in bipolar disorder encompasses several brain regions, including the prefrontal cortex, amygdala, hippocampus, and basal ganglia. Dysregulation within these circuits contributes to the mood instability, impulsivity, and cognitive impairments characteristic of the disorder.

Prefrontal Cortex: The prefrontal cortex is essential for executive functions, decision-making, and emotion regulation. In bipolar disorder, dysregulation in this region is associated with mood instability, impaired judgment, and cognitive deficits. Functional imaging studies have shown reduced activity in the prefrontal cortex during depressive episodes and increased activity during manic episodes.

Amygdala: The amygdala plays a critical role in processing emotions and threat-related stimuli. Hyperactivity in the amygdala is often observed during manic episodes, contributing to heightened emotional responses and impulsivity. Conversely, hypoactivity in the amygdala during depressive episodes can result in blunted affect and emotional withdrawal.

-Hippocampus: The hippocampus is involved in memory formation and contextual processing. Structural and functional abnormalities in the hippocampus are linked to cognitive impairments and mood dysregulation in bipolar disorder. Reduced hippocampal volume and connectivity have been associated with both manic and depressive symptoms.

Basal Ganglia: The basal ganglia are involved in motor control, reward processing, and habit formation. Dysregulation in this region, particularly in the striatum, is associated with the hyperactivity and risk-taking behaviors observed during manic episodes. Additionally, altered basal ganglia function can contribute to psychomotor retardation and anhedonia during depressive episodes.

Neurochemical Basis of Bipolar Disorder

Clinical studies over the past decades have attempted to uncover the biological factors mediating the pathophysiology of bipolar disorder (BD) utilizing a variety of biochemical and neuroendocrine strategies. Indeed, assessments of cerebrospinal fluid chemistry, neuroendocrine responses to pharmacological challenge, and neuroreceptor and transporter binding have demonstrated a number of abnormalities in the amine neurotransmitter systems in this disorder. However, recent studies have also implicated critical signal transduction pathways as being integral to the pathophysiology and treatment of BD, in addition to a growing body of data suggesting that impairments of neuroplasticity and cellular resilience may also underlie the pathophysiology of the disorder. It is thus noteworthy that mood stabilizers and antidepressants indirectly regulate a number of factors involved in cell survival pathways - including MAP kinases, CREB, BDNF and bcl-2 protein - and may thus bring about some of their delayed long-term beneficial effects via underappreciated neurotrophic effects.

Although genetic factors play a major, unquestionable role in the etiology of bipolar disorder (BD), the biochemical abnormalities underlying the predisposition to and the pathophysiology of BD remain to be fully elucidated. Early biologic theories regarding the pathophysiology of BD have focused upon various neurotransmitters, in particular the biogenic amines. In recent years, however, advances in our understanding of the cellular mechanisms underlying neuronal communication have focused research into the role of post-receptor sites. Indeed, the 'molecular medicine revolution' has resulted in a more complete understanding of the etiology and pathophysiology of a variety of medical disorders. However, in contrast to the progress that has been made in elucidating the etiology and/or pathophysiology of a variety of medical conditions, we have yet to identify the specific abnormal genes or proteins in BD. (Belmaker & Agam, 2008) The behavioral and physiological manifestations of BD are complex and must account not only for the profound changes in mood, but also for the constellation of neurovegetative and psychomotor features. The pathophysiology is undoubtedly mediated by a network of interconnected limbic, striatal and fronto-cortical neurotransmitter neuronal circuits, and the interacting cholinergic, catecholaminergic and serotonergic neurotransmitter systems thus represent very attractive candidates. Thus, it is not surprising that clinical studies over the past 40 years have for the most part rested upon the conceptual foundation that monoamine signaling and hypothalamic-pituitary-adrenal (HPA) axis disruption are integral to the pathophysiology of both depression and mania.

A true understanding of the pathophysiology of BD must address its neurobiology at different physiological levels, i.e. molecular, cellular, systems, and behavioral. Abnormalities in gene expression undoubtedly underlie the neurobiology of the disorder at the molecular level and this will become evident as we identify the susceptibility and protective genes for BD in the coming years. Once this has been accomplished, however, the even more difficult work must begin to examine the impact of the faulty expression of these gene-products (proteins) on integrated cell function. It is at these levels that some compelling protein candidates have been identified as the targets for the actions of mood stabilizing agents; however, the precise manner in which these candidate molecular and cellular targets may or may not relate to the faulty expression of susceptibility gene products is yet to be determined. The task becomes even more daunting when one considers the possibility that a major component of the pathophysiology of BD may stem from discordant biological rhythms ranging from ultradian to infradian that ultimately drive the periodic recurrent nature of the disorder. The subsequent challenge for the basic and clinical neuroscientist will be the integration of these molecular/cellular changes to the systems and ultimately to the behavioral level wherein the clinical expression of BD becomes fully elaborated. However, considerable progress has been made in our understanding of this fascinating but devastating mental disorder.

Neurochemical Basis of Anxiety Disorder

Fear and anxiety normally comprise adaptive responses to threat or stress. These emotional-behavioral sets may arise in response to exteroceptive visual, auditory, olfactory, or somatosensory stimuli or to interoceptive input through the viscera and the endocrine and autonomic nervous systems.

Anxiety may also be produced by cognitive processes mediating the anticipation, interpretation, or recollection of perceived stressors and threats. Emotional processing in general can be divided into evaluative, expressive, and experiential components. Evaluation of the emotional salience of a stimulus involves appraisal of its valence (e.g., appetitive versus aversive), its relationship with previous conditioning and behavioral reinforcement experiences, and the context in which it arises. Emotional expression conveys the range of behavioral, endocrine, and autonomic manifestations of the emotional response, whereas emotional experience describes the subjective feeling accompanying the response. To optimize their capacity for guiding behavior, all these aspects of emotional processing are modulated by complex neurobiological systems that prevent them from becoming persistent, excessive, inappropriate to reinforcement contingencies, or otherwise maladaptive. The emotional processes pertaining to fear and anxiety that have been most extensively studied (largely because of their amenability to experimental manipulation) have involved pavlovian fear conditioning and fear-potentiated startle. These types of "fear learning" have been shown to comprise experience-dependent forms of neural plasticity in an extended anatomic network that centers around the critical involvement of the amygdala. (barbini et al., 2003)

The structures that function in concert with the amygdala during fear learning include other mesiotemporal cortical structures, the sensory thalamus and cortices, the orbital and medial prefrontal cortex (mPFC), the anterior insula, the hypothalamus, and multiple brainstem nuclei. Much of this network appears to participate in the general process of associating a conditioned stimulus (CS) or operant behavior with an emotionally salient or operant behavior with an emotionally salient unconditioned stimulus.

Neurochemical Basis of Fear and Anxiety

The neuroanatomic circuits that support fear and anxiety behavior are modulated by a variety of chemical neurotransmitter systems. These include the peptidergic neurotransmitters, CRH, neuropeptide Y (NPY), and substance P, the monoaminergic transmitters, NE, serotonin (5-hydroxytryptamine or 5-HT), and dopamine (DA), and the amino acid transmitters, GABA and glutamate. The neurotransmitter systems that have been best studied in association with responses to stress or threat involve the HPA axis and the central noradrenergic system. These neurochemical systems sub serve important adaptive functions in preparing the organism for responding to threat or stress, by increasing vigilance, modulating memory, mobilizing energy stores, and elevating cardiovascular function. Nevertheless, these biological responses to threat and stress can become maladaptive if they are chronically or inappropriately activated. Additional neurochemical systems that play important roles in modulating stress responses and emotional behavior include the central GABAergic, serotonergic, dopaminergic, opiate, and NPY systems. The preclinical and clinical literature regarding these neurochemical concomitants of stress and fear and their potential relevance to the pathophysiology of anxiety disorders are reviewed in the following sections. (Chou, et al., 2020)

Functional Interactions among Noradrenergic, HPA, and CRH Systems Coordinated functional interactions between the HPA axis and the noradrenergic systems play major roles in producing adaptive responses to stress, anxiety, or fear. The secretion of CRH increases LC neuronal firing activity and results in enhanced NE release in a variety of cortical and subcortical regions. Conversely, NE release stimulates CRH secretion in the PVN (the nucleus containing most of the CRH-synthesizing neurons in the hypothalamus).

During chronic stress in particular, the LC is the brainstem noradrenergic nucleus that appears preferentially to mediate NE release in the PVN. Conversely, as CRH release in the PVN stimulates ACTH secretion from the pituitary and thereby increases cortisol secretion from the adrenal glands, the rise in plasma cortisol concentrations acts through a negative feedback pathway to decrease both CRH and NE synthesis at the level of the PVN. Glucocorticoid-mediated inhibition of NE-induced CRH stimulation may be evident primarily during stress, rather than under resting conditions, as an adaptive response that restrains stress-induced neuroendocrine and cardiovascular effects mediated by the PVN. NE, cortisol, and CRH thus appear tightly linked as a functional system that offers a homeostatic mechanism for responding to stress. A clinical phenomenon of anxiety disorders that may be specifically regulated by interactions between NE and glucocorticoid secretion involves the acquisition and consolidation of traumatic memories. A characteristic feature of PTSD and PD is that memories of the traumatic experience or the original panic attack, respectively, persist for decades and are recalled in response to multiple stimuli or stressors. In experimental animals, alterations of both brain catecholamine and glucocorticoid levels affect the consolidation and retrieval of emotional memories. Glucocorticoids influence memory storage by activation of glucocorticoid receptors in the hippocampus, whereas NE effects are mediated in part through -adrenoreceptor stimulation in the amygdala. In humans, adrenocortical suppression blocks the memory-enhancing effects of amphetamine and epinephrine, and propranolol impairs memory for an emotionally provocative story, but not for an emotionally "neutral" story. These data suggest that the acute release of glucocorticoids and NE in response to trauma may modulate the encoding of traumatic memories. It is conceivable that long-term alterations in these systems may account for memory distortions seen in PTSD, such as the memory fragmentation, hypermnesia, and deficits in declarative memory. (Zhang, et al., 2018)

Central Benzodiazepine-GABA–Receptor System Several lines of preclinical and clinical evidence have established that BZD-receptor agonists exert anxiolytic effects and have suggested that BZD-receptor function may be altered in anxiety disorders. Central BZD receptors are expressed are present throughout the brain, but they are most densely concentrated in the cortical gray matter. The BZD and GABAA receptors form parts of the same macromolecular complex, and although they constitute distinct binding sites, they are functionally coupled and regulate each other in an allosteric manner. Central BZD-receptor agonists potentiate and prolong the synaptic actions of the inhibitory neurotransmitter, GABA, by increasing the frequency of GABA-mediated chloride channel openings. Microinjection of BZD-receptor agonists in limbic and brainstem regions such as the amygdala and the PAG exert antianxiety effects in animal models of anxiety and fear. Conversely, administration of BZD-receptor inverse agonists, such as -carboline-3-carboxylic acid ethylester, produces behaviors and increases in heart rate, blood pressure, plasma cortisol, and catecholamines similar to those seen in anxiety and stress, effects that can be blocked by administration of BZD-receptor agonists. Transgenic mouse studies have identified behavioral roles for specific GABAA-receptor subunits. The anxiolytic action of diazepam appears absent in mice with 2 subunit point mutations, but it is present in mice with 1 or 3 subunit point mutations. These data suggest that the anxiolytic effect of BZD agonists is at least partly mediated by the GABAA-receptor 2 subunit, which is largely expressed in the limbic system, but not by the 3subunit, which is predominately expressed in the reticular activating system, or the 1 subunit, which is implicated in mediating the sedative, amnestic, and anticonvulsive effects of BZDs. These findings hold clear implications for investigations of the pathophysiology of anxiety disorders and for the development of anxioselective BZD-receptor agonists. Some other agents with anxiolytic effects appear to modulate the function of the GABAA/BZD-receptor–chloride ionophore complex by mechanisms distinct from those of the BZD agonists. (Grace, 2016).

The neurosteroid, allopregnenolone, exerts antianxiety effects in conflict paradigms that serve as putative animal models of anxiety. The anticonflict effects of allopregnenolone are reversed by either isopropylbicyclophosphate, which binds at the picrotoxinin site on the GABAA receptors, or RO15-4513(ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4Himidazo[1,5-]-[1,4] benzodiazepine-3-carboxylate), a BZD-receptor inverse agonist that inhibits GABAA-activated chloride flux in neuronal membranes. In contrast, administration of the BZD-receptor antagonist flumazenil (ethyl-8-fluoro-5,6-dihydro-5-methyl6-oxo-4H-imidazo[1,5-]-[1,4]benzodiazepine-3- carboxylate) does not block allopregnenolone's anxiolytic-like effects, a finding indicating that allopregnenolone does not bind at the BZD site. Allopregnenolone may thus exert anxiolytic-like effects by stimulating the chloride channel in GABAA receptors by binding at the picrotoxinin site or at a site specific for RO15-4513. The antianxiety effects of antidepressant drugs with pri mary effects on monoamine reuptake may also be partly mediated through a GABAergic mechanism. These agents are effective for the treatment of a spectrum of anxiety disorders including social anxiety disorder, generalized anxiety disorder, PD, and PTSD. One of the multiple secondary effects of these agents involves potentiation of GABAergic function. For example, in rats, the effective dose of phenelzine (15mg/kg) on the elevated plus maze administered produces a more than twofold increase in whole-brain level GABA concentrations, whereas an ineffective dose of phenelzine (5.1 mg/kg) does not significantly alter GABA levels . Moreover, the N-acetylated metabolite of phenelzine, N-2-acetylphenelzine, which potently inhibits monoamine oxidase but does not change whole-brain GABA concentrations, does not produce anxiolytic effects in the elevated plus-maze test. Phenelzine's anxiolytic effects in the plus-maze model may thus depend on elevating brain GABA concentrations, in contrast to the mechanism of the classic BZDs, which instead increase the affinity of GABAA receptors for GABA. (Grace, 2016).

Effects of Stress on Benzodiazepine-GABAA Receptors BZD- and GABA-receptor function can be altered by exposure to stress in some brain regions. In experimental animals exposed to inescapable stress in the form of cold swim or foot shock, the BZD-receptor binding decreases in the frontal cortex, with less consistent reductions occurring in the hippocampus and hypothalamus, but no changes in the occipital cortex, striatum, midbrain, thalamus, cerebellum, or pons. Chronic stress in the form of repeated foot shock or cold-water swim resulted in decreased BZD-receptor binding in the frontal cortex and hippocampus, and possibly in the cerebellum, midbrain, and striatum, but not in the occipital cortex or pons. These reductions in BZD-receptor binding were associated with deficits in maze escape behaviors that may have reflected alterations in mnemonic processing. Some of these stress effects may be mediated by glucocorticoids, because chronic exposure to stress levels of CORT alters mRNA levels of multiple GABAA-receptor subunits (271). Consistent with the effects of chronic stress on BZD-receptor expression, the Maudsley "genetically fearful" rat strain shows decreased BZD-receptor density relative to other rats in several brain structures including the hippocampus (272). Stressors arising early in life may also influence the development of the GABAergic system. In rats, early-life adverse experiences such as maternal separation result in decreased GABAA-receptor concentrations in the LC and the NTS, reduced BZD-receptor sites in the LC, the NTS, the frontal cortex, and the CE and the LA of the amygdala, and reduced mRNA levels for the 2 subunits of the GABAA-receptor complex in the LC, the NTS, and the amygdala (273). The extent to which these developmental responses to early-life. (Nuss, P. 2015).

Benzodiazepine-GABA–Receptor Function in Anxiety Disorders The central BZD receptor has been implicated in anxiety disorders on the basis of the anxiolytic and anxiogenic properties of BZD agonists and inverse agonists, respectively, and by the evidence that the BZD-receptor sensitivity to BZD agonists is reduced in some anxiety-disordered subjects. Hypotheses advanced regarding the role of GABAA-BZD–receptor function in anxiety disorders have proposed either that changes in the GABAA-BZD macromolecular complex conformation or that alterations in the concentration or properties of an endogenous ligand account for the pathologic anxiety symptoms seen in anxiety disorders. However, these hypotheses have not been conclusively tested by in vivo or postmortem studies of anxietydisordered humans. In PD, oral and intravenous administration of the BZD-receptor antagonist, flumazenil, produces panic attacks and increases anticipatory anxiety in some subjects with PD, but not in healthy controls. In addition, the sensitivity to the effects of diazepam on saccadic eye movement velocity is abnormally reduced in PD, a finding implying that the functional sensitivity of the GABAA-BZD supramolecular complex is attenuated in brainstem regions controlling saccadic eye movements. Subjects with PD also show abnormally reduced sensitivity to the suppressant effects of diazepam on plasma NE, epinephrine, and heart rate.

Receptor imaging studies using PET and SPECT have assessed central BZD-receptor binding in anxiety disorders. SPECT studies have reported reduced uptake of the selective BZD-receptor radioligand, iomazenil, in the frontal, temporal, and occipital, cortices in subjects with PD relative to control subjects. However, interpretation of these results was limited by the absence of medication-free PD study subjects and of healthy controls or by the dependence on nonquantitative methods for estimating BZD-receptor binding. A

SPECT-iomazenil study that quantitated BZD-receptor binding by derivation of distribution volumes found reduced binding in the left hippocampus and precuneus in unmedicated PD relative to healthy control samples and reported an inverse correlation between panic anxiety ratings and frontal cortex iomazenil binding. Another SPECT-iomazenil study reported lower distribution volumes for BZD receptors in the dorsomedial PFC in PTSD relative to control samples. These findings appeared consistent with the evidence cited earlier that stress downregulates BZD-receptor binding in the frontal cortex and the hippocampus of experimental animals. Central BZD-receptor binding has also been assessed in PD using PET and flumazenil. Maliziaetal. reported a global reduction in BZD site binding in seven study subjects with PD relative to eight healthy controls, with the most prominent decreases evident in the right orbitofrontal cortex and the right insula (areas consistently activated during normal anxiety processing. In contrast, Abadie et al. found no differences in the Bmax, Kd or bound/free values for flumazenil in any brain region in ten unmedicated PD study subjects relative to healthy controls. (Nuss, P. 2015).

Dopaminergic System Acute stress increases DA release and turnover in multiple brain areas. The dopaminergic projections to the mPFC appear particularly sensitive to stress, because brief or lowintensity stressors (e.g., exposure to fear-conditioned stimuli) increase DA release and turnover in the mPFC in the absence of corresponding changes in other mesotelencephalic dopaminergic projections. For example, in rats, low-intensity electric foot shock increases tyrosine hydroxylase activity and DA turnover in the mPFC, but not in the nucleus accumbens or the caudate-putamen. In contrast, stress of greater intensity or longer duration additionally enhances DA release and metabolism in other areas as well.

The regional sensitivity to stress appears to follow a pattern in which dopaminergic projections to the mPFC are more sensitive to stress than the mesoaccumbens and nigrostriatal projections, and the mesoaccumbens dopaminergic projections are more sensitive to stress than the nigrostriatal projections. Thus far, there is little evidence that dopaminergic dysfunction plays a primary role in the pathophysiology of human anxiety disorders. In PD, Roy-Byrne et al. found a higher plasma concentration of the DA metabolite, homovanillic acid (HVA), in patients with high levels of anxiety and frequent panic attacks relative to controls. Patients with PD were also shown to have a greater growth hormone response to the DA-receptor agonist, apomorphine, than depressed controls. However, Eriksson et al. found no evidence of alterations in the CSF HVA concentrations in patients with PD or for correlations between CSF HVA and anxiety severity or panic attack frequency. In addition, genetic studies examining associations between PD and gene polymorphisms for the DA D4 receptor and the DA transporter have produced negative results. In social phobia, two preliminary SPECT imaging studies involving small subject samples reported abnormal reductions in DA-receptor binding. Tiihonenetal. found a significant reduction in -CIT binding in the striatum in social phobic relative to healthy control samples, presumably reflecting a reduction in DA-transporter binding. Schneieretal. reported reduced uptake of the DA D2/D3- receptor radioligand, IBZM, in social phobic subjects relative to healthy control subjects. Both findings await replication. (Grace, A. A. 2016).

Neurochemical Aspects of Neurological Diseases

Neurological disorders constitute a group of diseases, which are characterized by a progressive deterioration of brain and spinal cord functions. Neurological disorders are classified into neurotraumatic diseases (stroke, traumatic brain injury, and spinal cord injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, and Huntington's disease), and neuropsychiatric diseases (tardive dyskinesia, major depression, and epilepsy). These diseases are accompanied by induction of excitotoxicity, oxidative stress, and neuroinflammation. Neurotraumatic diseases are accompanied by rapid decrease in adenosine triphosphate (ATP), loss of ion homeostasis along with neurodegeneration that occurs rapidly (hours to days). In contrast, neurodegenerative diseases involve slow decrease in ATP, limited maintenance of ion homeostasis, and accumulation of misfolded proteins leading to neurodegenerative processes that occur slowly (years) to develop. Neuropsychiatric diseases involve the alterations in signal transduction, changes in neurotransmitters along with induction of oxidative stress and neuroinflammation. This chapter will discuss the neurochemical aspects of neurological and neuropsychiatric disorders. (Sathappan, et al., 2019)

Neurodegenerative Diseases:

Degenerative diseases of the nervous system impose substantial medical and public health burdens on populations throughout the world. Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are three of the major neurodegenerative diseases. The prevalence and incidence of these diseases rise dramatically with age; thus, the number of cases is expected to increase for the foreseeable future as life spans in many countries continue to increase. Causal contributions from genetic and environmental factors are, with some exceptions, poorly understood. Nonetheless, molecular epidemiology approaches have proven valuable for improving disease diagnoses, characterizing disease prognostic factors, identifying high-risk genes for familial neurodegenerative diseases, investigating common genetic variants that may predict susceptibility for the non-familial forms of these diseases, and for quantifying environmental exposures. Incorporation of molecular techniques, including genomics, proteomics, and measurements of environmental toxicant body burdens into epidemiologic research, offer considerable promise for enhancing progress on characterizing pathogenesis mechanisms and identifying specific risk factors, especially for the non-familial forms of these diseases. brief overviews are provided of the epidemiologic features of PD, AD, and ALS, as well as illustrative examples in which molecular epidemiologic approaches have advanced knowledge on underlying disease mechanisms and risk factors that might lead to improved medical management and ultimately disease prevention. (Mally, et al., 2004)

Increasingly, epidemiologic research on neurodegenerative diseases has applied molecular techniques to identify host susceptibility factors to elucidate more clearly pathogenesis mechanisms, and to characterize exposures to potential environmental risk factors. Advances in molecular genetics and exposure measurement have facilitated expanded use of these techniques. Largely due to the ease and availability of genotyping assays, studies of candidate gene variants have been the most common applications. In this chapter, illustrations of the contributions of molecular epidemiology related primarily to elucidating disease pathogenesis processes and identifying etiologic factors will be presented. The focus will be on Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), as they share some common clinical, pathological and epidemiologic features. Other chronic neurological disorders, such as multiple sclerosis and Huntington’s disease, are also significant public health concerns, but will not be discussed in the interest of brevity.As background, brief descriptions of the clinical and pathological features of the three disorders will be provided, as well as summaries of epidemiologic aspects, including the relative contributions of genetics and the environment. (Mally, et al., 2004)

Alzheimer's Disease

Alzheimer's disease is a brain disorder that gets worse over time. It's characterized by changes in the brain that lead to deposits of certain proteins. Alzheimer's disease causes the brain to shrink and brain cells to eventually die. Alzheimer's disease is the most common cause of dementia — a gradual decline in memory, thinking, behavior and social skills. These changes affect a person's ability to function.

Alzheimer's disease is characterized by the gradual impairment of cognitive function, resulting in memory loss, decline in thinking abilities, and changes in behavior. Named after Alois Alzheimer, a German psychiatrist who first described the condition in 1906, Alzheimer's is primarily a disease of aging, typically affecting individuals over the age of 65. However, early-onset Alzheimer's can occur in individuals as young as their 40s or 50s. It is a progressive condition that worsens over time, leading to significant challenges in daily functioning and quality of life for both the affected individuals and their families and caregivers. (Lee, et al., 2016)

Pathology of Alzheimer's Disease:

In Alzheimer's disease, the brain undergoes significant structural and biochemical changes. The buildup of abnormal protein structures, such as beta-amyloid plaques and tau tangles, plays a central role in the disease's progression. Beta-amyloid plaques are formed from the accumulation of a protein called beta-amyloid, which clumps together and deposits between brain cells. These plaques can disrupt cell-to-cell communication, trigger inflammation, and damage brain cells. Tau tangles, on the other hand, are comprised of twisted fibers of a protein called tau, which normally helps to maintain the structure of brain cells. In Alzheimer's, tau proteins become hyperphosphorylated and form tangles inside nerve cells, leading to their dysfunction and eventual death. (Lee, et al., 2016)

Symptoms and Stages of Alzheimer's Disease:

Alzheimer's disease typically progresses through several stages, each characterized by distinct symptoms and levels of impairment. In the earliest stage, called mild cognitive impairment (MCI), individuals may experience mild memory loss and difficulties with concentration and word-finding. As the disease progresses to mild Alzheimer's, memory impairments become more evident, and individuals may start to have difficulty with tasks like managing finances or remembering recent events. In moderate Alzheimer's, memory loss worsens, and individuals may require assistance with daily activities such as dressing or bathing. Communication problems, behavioral changes, and confusion are also prevalent in this stage. In the final stage, severe Alzheimer's, individuals lose the ability to communicate, become bedridden, and require round-the-clock care. (Chou, et al., 2020)

Diagnosis of Alzheimer's Disease:

Diagnosing Alzheimer's can be challenging, as there is no definitive test available. Medical professionals primarily rely on a combination of patient history assessments, cognitive tests, neurological examinations, and brain imaging techniques to make an accurate diagnosis. They also exclude other possible causes of cognitive decline, such as depression, thyroid disorders, or certain medication side effects. While early detection is desirable, it can be difficult, as symptoms may be subtle and mimic natural aging or other conditions. However, ongoing research endeavors to develop reliable biomarkers and diagnostic methods to detect Alzheimer's at its earliest stages. (Chou, et al., 2020)

Management and Treatment of Alzheimer's Disease:

While there is currently no cure for Alzheimer's disease, several treatment options are available that can help manage symptoms and slow down disease progression. Medications called cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, can alleviate cognitive symptoms and temporarily improve memory and thinking abilities. Another medication called memantine is prescribed for individuals with moderate to severe Alzheimer's and helps regulate glutamate activity in the brain, which is involved in learning and memory. These pharmaceutical interventions may provide some relief, but their effects are modest and vary from person to person.

In addition to medication, non-pharmacological interventions are also vital in Alzheimer's management. Environmental modifications, such as creating a safe and structured living environment, can help reduce confusion and maintain independence for as long as possible. Occupational therapy can assist individuals in engaging in meaningful activities while compensating for cognitive impairments. Physical exercise has shown promising effects in improving cognitive function and reducing the risk of developing Alzheimer's. Furthermore, social engagement and mental stimulation, such as participating in social activities, hobbies, or puzzles, may help maintain cognitive abilities and slow down cognitive decline. (Chou, et al., 2020)

Caregiver Support and Impact on Families:

Alzheimer's disease not only affects individuals diagnosed with the condition but also has a profound impact on their families and caregivers. Providing care for someone with Alzheimer's can be emotionally, physically, and financially challenging. Caregivers often experience high levels of stress, depression, and burnout due to the demands of constant supervision, personal care assistance, and managing challenging behaviors. Support groups, respite care services, and counseling can be valuable resources for caregivers, offering emotional support, education, and practical guidance to navigate the caregiving journey.

Ongoing Research and Future Directions:

The search for effective treatments and a cure for Alzheimer's disease continues to be a major focus of scientific research. Studies investigate various aspects, including identifying new drug targets, exploring potential vaccines to target beta-amyloid plaques, and developing interventions to alleviate tau-related damages. Additionally, researchers aim to better understand the role of genetic and environmental risk factors, such as apolipoprotein E (APOE) gene variants and lifestyle factors, to develop strategies for prevention or early intervention. Emerging fields, such as biomarker research and artificial intelligence (AI)-based diagnostic tools, hold promise for early detection and more accurate diagnosis of Alzheimer's. Clinical trials and collaborations among scientists, institutions, and pharmaceutical companies worldwide drive the quest to unravel the mysteries of this devastating disease.

Alzheimer's disease is a complex and challenging condition that impacts millions of individuals and their loved ones. While there is no cure at present, ongoing research and advancements in detection, treatment, and care strategies provide hope for the future. A multidisciplinary approach that integrates pharmacological interventions, non-pharmacological therapies, caregiver support, and societal awareness is crucial in helping individuals with Alzheimer's live with dignity, maintaining their quality of life for as long as possible. Combining scientific efforts, healthcare advancements, and compassion, we strive to improve outcomes, bring relief to those affected, and eventually find a cure for Alzheimer's disease. . (Liao, et al., 2015)



Figure 1: Showing normal brain and Alzheimer brain

Alzheimer's disease is the most common form of dementia, accounting for around 60-80% of dementia cases. It primarily affects older adults, typically appearing after the age of 65, although early-onset Alzheimer's can occur in individuals younger than that.

The hallmark features of Alzheimer's disease are the accumulation of two abnormal protein structures in the brain. These proteins are called beta-amyloid plaques and tau tangles. Beta-amyloid plaques build up between brain cells, causing inflammation and cell death, while tau tangles form inside nerve cells, disrupting their ability to communicate with each other.

As the disease progresses, individuals may experience a range of symptoms beyond memory loss. These can include confusion, difficulty with problem-solving and decision-making, disorientation in time and place, challenges in language and communication, poor judgment, and changes in mood and personality. People with late-stage Alzheimer's become increasingly dependent on others for their daily care.

Diagnosing Alzheimer's disease usually involves a combination of medical history assessments, cognitive tests, neurological exams, and brain imaging. While there is currently no cure for Alzheimer's, treatments are available to manage symptoms and slow down the progression of the disease. These may include medications, therapy, and lifestyle interventions such as regular exercise, a balanced diet, and social engagement.

It is worth mentioning that Alzheimer's affects not only the individuals diagnosed but also

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder that affects approximately 10 million people worldwide. It is the second most common neurodegenerative disorder after Alzheimer's disease and primarily affects individuals over the age of 50. In this article, we will delve into the details of Parkinson's disease, exploring its etiology, symptoms, diagnosis, and treatment options. (Chou, et al., 2020)

Etiology of Parkinson's Disease:

The exact cause of Parkinson's disease is still unknown, but research suggests that it is a combination of both genetic and environmental factors. In 5-10% of cases, PD is caused by a specific genetic mutation, while the remaining cases are believed to be caused by a combination of genetic susceptibility and environmental triggers.

The key pathological feature of PD is the loss of dopamine-producing neurons in the substantia nigra region of the brain. Dopamine is a neurotransmitter that plays a crucial role in controlling movement and coordination. The progressive degeneration of these neurons results in a decrease in dopamine levels, leading to the characteristic motor symptoms of PD.

Symptoms of Parkinson's Disease:

The hallmark symptoms of Parkinson's disease include tremors, rigidity, bradykinesia (slowness of movement), and postural instability. These motor symptoms usually start on one side of the body and gradually spread to the other side. Other non-motor symptoms of PD include sleep disturbances, constipation, loss of sense of smell, depression, and cognitive impairment.

The severity and progression of symptoms can vary greatly from person to person, and the rate of disease progression can also vary. Some individuals may experience rapid progression of symptoms, while others may have a more gradual decline over several years.

Diagnosis of Parkinson's Disease:

Currently, there is no definitive test to diagnose Parkinson's disease. The diagnosis is based on clinical features and exclusion of other conditions. A thorough physical examination, medical history, and neurological evaluation are essential for a PD diagnosis. Brain imaging techniques, such as MRI and PET scans, may also be used to rule out other conditions.

There are also several clinical rating scales, such as the Unified Parkinson's Disease Rating Scale (UPDRS), which are used to assess the severity of symptoms and track disease progression.

Treatment of Parkinson's Disease:

There is currently no cure for Parkinson's disease, but treatment options are available to manage symptoms and improve quality of life. Medications such as levodopa, dopamine agonists, and MAO-B inhibitors can help replace dopamine levels in the brain and improve motor symptoms.

Physical therapy, occupational therapy, and speech therapy can also help manage symptoms and enhance mobility and communication. Deep brain stimulation, a surgical procedure that involves implanting electrodes in the brain, is another treatment option for advanced cases of PD.

Besides medical treatment, lifestyle modifications such as regular exercise, a healthy diet, and stress management can also help manage PD symptoms. It is essential for individuals with PD to have a strong support system and to work closely with their healthcare team to manage the disease effectively.

Challenges of Living with Parkinson's Disease:

Parkinson's disease can have a significant impact on an individual's daily life, and as the disease progresses, it can become increasingly challenging to manage. Motor symptoms such as tremors, rigidity, and slowness of movement can interfere with everyday activities such as dressing, eating, and writing.

Non-motor symptoms, such as depression, anxiety, and cognitive impairment, can also have a significant impact on an individual's quality of life. The unpredictable nature of the disease and the progression of symptoms can also cause emotional distress not only for individuals with PD but also for their caregivers. (Yang, et al., 2018).



Figure 2: Parkinson diseases patient showing brain cells with protein lumps

Role of Neurochemicals in Neurological Diseases

Neurochemicals, or neurotransmitters, are essential for the proper functioning of the nervous system, influencing a wide range of neurological processes and behaviors. Their dysregulation is a hallmark of various neurological diseases, profoundly impacting the pathophysiology and clinical manifestations of these conditions. In Alzheimer's disease (AD), for instance, the degeneration of cholinergic neurons leads to a significant reduction in acetylcholine levels, impairing memory and cognitive functions. This loss of acetylcholine is central to the cognitive deficits observed in AD, and therapies that enhance cholinergic transmission, such as acetylcholinesterase inhibitors, have been developed to mitigate these symptoms. Similarly, in Parkinson's disease (PD), the degeneration of dopaminergic neurons in the substantia nigra results in a substantial decrease in dopamine levels, which is critical for motor control. This dopamine deficiency leads to the characteristic motor symptoms of PD, including tremors, rigidity, and bradykinesia. Dopaminergic therapies, such as levodopa, aim to replenish dopamine levels and alleviate these motor symptoms, highlighting the crucial role of dopamine in PD pathology. (Yang, et al., 2018).

Beyond AD and PD, neurochemicals are implicated in a myriad of other neurological diseases, each with distinct neurochemical alterations contributing to their unique symptomatology. In epilepsy, an imbalance between excitatory neurotransmitters like glutamate and inhibitory neurotransmitters like gamma-aminobutyric acid (GABA) leads to abnormal neuronal excitability and recurrent seizures. Enhancing GABAergic transmission or reducing glutamatergic activity forms the basis of many antiepileptic drugs, which aim to restore the excitatory-inhibitory balance and prevent seizure activity. In multiple sclerosis (MS), the demyelination of neurons disrupts normal neurotransmission, affecting a range of neurochemical systems. This disruption contributes to the diverse neurological symptoms seen in MS, including motor deficits, sensory disturbances, and cognitive impairments. Neuroinflammation, characterized by the release of pro-inflammatory cytokines, further exacerbates neurochemical dysregulation in MS, contributing to disease progression. Targeting these neurochemical pathways and modulating neuroinflammatory responses are emerging therapeutic strategies aimed at mitigating symptoms and slowing disease progression in MS. Collectively, these examples underscore the fundamental roles of neurochemicals in neurological diseases and the importance of targeting these pathways for therapeutic interventions.

In addition to the specific diseases mentioned, the broader landscape of neurological disorders showcases the intricate interplay of various neurochemical systems. For instance, in Huntington's disease, a genetic neurodegenerative disorder, there is a significant loss of GABAergic and cholinergic neurons in the striatum, which leads to motor dysfunction, psychiatric symptoms, and cognitive decline. This neurochemical imbalance contributes to the characteristic involuntary movements, mood swings, and cognitive impairment associated with the disease. Therapies that target these neurochemical pathways, such as GABAergic modulators, are being investigated to alleviate symptoms and improve the quality of life for patients. (Yang, et al., 2018).

Similarly, in amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease affecting motor neurons, glutamate excitotoxicity is a major pathological feature. Excessive glutamate release and impaired uptake lead to neuronal damage and death. Riluzole, a drug that modulates glutamatergic neurotransmission, has been shown to prolong survival and slow disease progression in ALS patients. This highlights the critical role of targeting glutamate dysregulation in therapeutic strategies for ALS.

Neurochemical imbalances are also prominent in psychiatric disorders, which often overlap with neurological conditions. For example, in schizophrenia, dysregulation of dopamine, glutamate, and GABA systems contributes to the positive, negative, and cognitive symptoms of the disorder. Antipsychotic medications primarily target dopamine receptors to alleviate psychotic symptoms, while ongoing research explores glutamatergic and GABAergic interventions to address cognitive deficits and negative symptoms.

Furthermore, the role of neuroinflammation in neurochemical dysregulation is gaining recognition in various neurological diseases. In conditions like traumatic brain injury (TBI) and stroke, the acute inflammatory response following injury leads to the release of pro-inflammatory cytokines, which can disrupt neurotransmitter systems and contribute to secondary neuronal damage. Modulating neuroinflammatory pathways to protect neurotransmitter function and promote recovery is an area of active investigation. (Berridge, & Robinson, 1998).

Neurotransmitter Deficiencies

Neurotransmitter deficiencies are a group of rare inherited disorders that affect the production, storage, or reuptake of certain neurotransmitters in the brain. Neurotransmitters are chemical messengers that allow nerve cells to communicate with each other. When there is a deficiency of a particular neurotransmitter, it can disrupt these communications and lead to a variety of neurological symptoms.

There are many different types of neurotransmitter deficiencies, but some of the most common include:

Dopamine Deficiency:

Dopamine, often hailed as the brain's "feel-good" chemical, plays a much more nuanced role than just pleasure. It acts as a vital neurotransmitter, a messenger molecule that facilitates communication between neurons. When dopamine levels dip below a healthy threshold, a condition known as dopamine deficiency arises. This deficiency disrupts the intricate dance of brain function, leading to a cascade of physical and mental health challenges.

Dopamine's Symphony of Roles:

Imagine a bustling orchestra, where each instrument represents a specific brain function. Dopamine acts like the conductor, ensuring all the sections work together seamlessly. It influences a range of crucial processes, including:

- Movement: Dopamine plays a central role in the control and coordination of movement. It helps us initiate actions, maintain posture, and navigate the world smoothly. A deficiency can manifest as tremors, stiffness, slowness of movement (bradykinesia), and difficulty with balance and coordination.
- Motivation and Reward: Dopamine fuels our drive and motivation. It creates a sense of anticipation and reward when we engage in goal-directed behavior. Deficiency can lead to a lack of motivation, making it difficult to initiate tasks or complete them once started. The absence of that rewarding feeling can make it challenging to find pleasure in activities we once enjoyed.
- Learning and Memory: Dopamine is essential for reinforcing new information and forming memories. It helps us learn from experiences and motivates us to repeat

behaviors that have positive consequences. Deficiency can impair our ability to learn new skills, consolidate memories, and make it difficult to focus and concentrate.

- Mood Regulation: While serotonin is often considered the key player in mood, dopamine also contributes to our emotional well-being. It helps regulate feelings of pleasure, satisfaction, and motivation, which indirectly influence mood. Deficiency can contribute to symptoms of depression, anxiety, and apathy. (Berridge, & Robinson, 1998).

The Cascade of Symptoms:

When dopamine deficiency disrupts these vital functions, a cascade of symptoms can emerge. These can vary depending on the severity of the deficiency and the individual's specific brain chemistry. Here's a closer look at some common manifestations:

- Movement Disorders: Parkinson's disease is the most well-known example of a condition associated with dopamine deficiency. It causes tremors, stiffness, slowness of movement, and difficulty with balance.
- Restless Legs Syndrome (RLS): This condition is characterized by an irresistible urge to move the legs, often accompanied by uncomfortable sensations, especially at night. Dopamine deficiency plays a role in the abnormal nerve activity that underlies RLS.
- Executive Dysfunction: This term refers to a group of cognitive skills that are crucial for planning, organizing, initiating tasks, and managing time. Dopamine deficiency can impair these skills, leading to difficulties with daily functioning.
- Depression and Anxiety: The lack of motivation, reward, and pleasure associated with dopamine deficiency can contribute to symptoms of depression and anxiety. People may experience low mood, loss of interest in activities, fatigue, and difficulty concentrating.
- Attention Deficit Hyperactivity Disorder (ADHD): While the exact causes of ADHD are complex, dopamine dysfunction is believed to play a role. Symptoms can include difficulty focusing, hyperactivity, impulsivity, and problems with organization. (Berridge, & Robinson, 1998).

Diagnosis and Treatment**:**

Dopamine deficiency is not a single, easily diagnosed condition. It can be associated with various underlying medical conditions, making a thorough evaluation from a healthcare professional crucial.

Diagnosis often involves a combination of neurological examinations, medical history review, and sometimes, brain imaging studies. There's no cure for dopamine deficiency itself; however, various treatment approaches can help manage the symptoms and improve quality of life. These include:

- Medications: Levodopa, a medication that increases dopamine production in the brain, is a mainstay treatment for Parkinson's disease and other conditions with severe motor symptoms. Dopamine agonists are another class of medications that mimic the effects of dopamine.
- Therapy**:** Physical therapy can help improve movement and coordination, while occupational therapy can assist with daily living activities. Cognitive-behavioral therapy can be helpful for managing symptoms of depression, anxiety, and ADHD.
- Lifestyle Changes**:** Getting regular exercise, maintaining a healthy diet, and prioritizing sleep can all contribute to managing dopamine deficiency.

Living with Dopamine Deficiency:

Dopamine deficiency can be a challenging condition, but with proper diagnosis and treatment, it can be managed effectively. By understanding the role of dopamine and the impact of its deficiency, individuals can work with their healthcare team to develop a personalized treatment plan and improve their overall well-being.



Figure 3: Dopamine Structure

Dopamine Molecule

Serotonin Deficiency: Serotonin, often hailed as the brain's "happiness chemical," plays a much wider role than just mood regulation. It acts as a multifaceted neurotransmitter, influencing everything from sleep and appetite to digestion and learning. When serotonin levels dip below a healthy threshold, a condition known as serotonin deficiency arises. This deficiency disrupts the intricate dance of brain function, leading to a cascade of physical and mental health challenges. (Berridge, & Robinson, 1998).

Serotonin's Symphony of Roles:

Imagine a well-lit stage where a play unfolds, each actor representing a brain function. Serotonin acts as the stage manager, ensuring a smooth performance by all the actors. It has a hand in a range of crucial processes, including:

- **Mood Regulation:** While not the sole player, serotonin is a key contributor to mood. It helps us experience feelings of happiness, well-being, and contentment. Deficiency can lead to symptoms of depression, anxiety, and irritability.
- **Sleep Regulation:** Serotonin plays a crucial role in regulating our sleep-wake cycle. It helps us fall asleep, stay asleep, and wake feeling refreshed. Deficiency can disrupt sleep patterns, leading to insomnia, fatigue, and daytime sleepiness.
- **Appetite Regulation:** Serotonin influences our appetite and feelings of satiety (feeling full). Deficiency can contribute to increased cravings for carbohydrates and sugary foods, leading to weight gain or difficulty managing weight.
- **Digestion:** Serotonin also plays a role in gut motility and digestion. Deficiency can contribute to digestive issues like constipation, diarrhea, or irritable bowel syndrome (IBS).
- **Learning and Memory:** Although less well-known, serotonin also has an impact on learning and memory consolidation. Deficiency can impair our ability to learn new information and retain memories.

The Cascade of Symptoms:

When serotonin deficiency disrupts these vital functions, a cascade of symptoms can emerge. These can vary depending on the severity of the deficiency and the individual's specific brain chemistry. Here's a closer look at some common manifestations:

- **Depression:** Symptoms can include low mood, loss of interest in activities, fatigue, changes in appetite and sleep, feelings of worthlessness, and difficulty concentrating.
- **Anxiety:** This can manifest as feelings of worry, nervousness, restlessness, difficulty relaxing, and physical symptoms like rapid heartbeat and shortness of breath.
- **Sleep Problems:** Difficulty falling asleep, staying asleep, waking up feeling unrested, and vivid dreams are common.
- **Digestive Issues:** Constipation, diarrhea, abdominal pain, and bloating can occur.
- **Decreased Libido:** Both men and women may experience a decreased interest in sex.
- **Cognitive Issues:** Difficulty concentrating, forgetfulness, and trouble learning new things can arise.

The Connection to Other Neurotransmitter Deficiencies:

The brain is a complex network where neurotransmitters work in concert. Serotonin deficiency can often coexist with deficiencies of other neurotransmitters, like dopamine and norepinephrine. This can create a more complex picture of symptoms. For example, a combination of serotonin and dopamine deficiency might lead to symptoms of both depression and apathy (lack of motivation). (Holsboer, F. 2000).

Diagnosis and Treatment:

Similar to dopamine deficiency, there's no single test for serotonin deficiency. Diagnosis often involves a combination of a mental health evaluation, medical history review, and sometimes, blood tests to rule out other medical conditions. There's no cure for serotonin deficiency itself, but various treatment approaches can help manage the symptoms and improve quality of life. These include:

- **Medications:** Selective serotonin reuptake inhibitors (SSRIs) are the most common class of medications used to treat serotonin deficiency. They work by preventing the reuptake of serotonin by neurons, thereby increasing its availability in the brain.

- **Therapy:** Psychotherapy, such as cognitive-behavioral therapy (CBT), can be helpful for managing symptoms of depression and anxiety.
- **Lifestyle Changes:** Getting regular exercise, maintaining a healthy diet rich in tryptophan (a precursor to serotonin), and prioritizing sleep can all contribute to managing serotonin deficiency.

Living with Serotonin Deficiency: Serotonin deficiency can be a challenging condition, but with proper diagnosis and treatment, it can be managed effectively. By understanding the role of serotonin and the impact of its deficiency, individuals can work with their healthcare team to develop a personalized treatment plan and improve their overall well-being. (Reeves, et al. 2002).

Enzyme Dysfunction

Neurotransmitter deficiencies, those imbalances in the brain's chemical messengers, often have a hidden culprit: enzyme dysfunction. Enzymes, the body's tireless biochemists, play a critical role in the intricate dance of neurotransmitter production, breakdown, and reuptake. When these enzymes malfunction, it can throw the entire system out of whack, leading to a cascade of problems.

The Enzyme Connection:

Imagine a neurotransmitter factory within the brain. Here's where the magic happens:

1. Raw Materials**:** Essential amino acids and other precursors are brought in.
2. Assembly Line**:** Specific enzymes act as the factory workers, each with a designated task. They catalyze (speed up) specific chemical reactions to transform these precursors into neurotransmitters like dopamine, serotonin, or norepinephrine.
3. Quality Control**:** Other enzymes function as the clean-up crew, breaking down used neurotransmitters or regulating their levels.

Enzyme Dysfunction Disrupts Production**:**

When enzymes malfunction due to mutations, deficiencies, or other factors, this neurotransmitter factory grinds to a halt. Here's how it can affect production:

- Limited Raw Materials: If enzymes involved in converting precursor molecules into usable forms are dysfunctional, there's a shortage of building blocks for neurotransmitter production.
- Stalled Assembly Line: Malfunctioning enzymes can create bottlenecks in the production line, hindering the conversion of precursors into neurotransmitters.
- Inefficient Breakdown: If enzymes responsible for breaking down used neurotransmitters are impaired, they can linger in the synaptic cleft, disrupting communication between neurons.

The Result: Neurotransmitter Deficiencies:

These disruptions in the neurotransmitter factory lead to deficiencies. Depending on the specific enzyme and neurotransmitter affected, various symptoms can arise:

- Dopamine Deficiency: This can manifest as tremors, stiffness, slowness of movement, and difficulty with motivation (Parkinson's disease).
- Serotonin Deficiency: Symptoms can include depression, anxiety, sleep problems, and digestive issues.
- Norepinephrine Deficiency: This might lead to fatigue, dizziness, and difficulty concentrating.

Examples of Enzyme Dysfunction in Neurotransmitter Deficiencies:

- Phenylketonuria (PKU): This genetic disorder results in a deficiency of the enzyme phenylalanine hydroxylase, which is crucial for converting the amino acid phenylalanine into tyrosine. Tyrosine is a precursor for dopamine, norepinephrine, and epinephrine. Deficiency can lead to intellectual disability and other neurological problems.
- Dopa Decarboxylase (DDC) Deficiency: This rare genetic condition affects the enzyme responsible for converting L-DOPA (levodopa) into dopamine. Levodopa is often a medication used to treat Parkinson's disease, but without DDC, it cannot be effectively converted to dopamine in the brain, limiting its effectiveness.
- Monoamine Oxidase A (MAO-A) Deficiency: This condition involves a malfunction in the enzyme MAO-A, which breaks down dopamine, serotonin, and norepinephrine. When MAO-A is deficient, these neurotransmitters linger in the

synaptic cleft for too long, potentially leading to symptoms of anxiety or even a serotonin syndrome (a potentially life-threatening condition). (Reeves, et al. 2002).

Therapeutic Approaches

Brain stimulation has become one of the most acceptable therapeutic approaches in recent years and a powerful tool in the remedy against neurological diseases. Brain stimulation is achieved through the application of electric currents using non-invasive as well as invasive techniques. Recent technological advancements have evolved into the development of precise devices with capacity to produce well-controlled and effective brain stimulation. Currently, most used non-invasive techniques are repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), whereas the most common invasive technique is deep brain stimulation (DBS). In last decade, application of these brain stimulation techniques has not only exploded but also expanded to wide variety of neurological disorders. Therefore, in the current review, we will provide an overview of the potential of both non-invasive (rTMS and tDCS) and invasive (DBS) brain stimulation techniques in the treatment of such brain diseases. (Kandel, et al., 2000)

There are two modalities of brain stimulation: non-invasive and invasive, and along the time, several techniques have been developed within both categories .The non-invasive stimulation is done by two techniques: transcranial magnetic stimulation (TMS), which was introduced in 1985, and transcranial electrical stimulation (tES). The transcranial direct current stimulation (tDCS) is the most modern and most used form of tES. These non-invasive techniques are applied directly through electrodes or magnetic fields on the scalp of the patient to produce electrical currents for the stimulation of brain cells. However, invasive stimulation, such as deep brain stimulation (DBS), involves passing electric current into the subcortical area through surgically implanted electrodes deeper in the brain. Unlike invasive, non-invasive methods do not require anesthesia and surgical operation, and therefore, these are preferred over invasive methods. Both non-invasive techniques, rTMS and tDCS, have been used in clinical settings, are already regulated for clinical use in many countries and, currently, are approved by the Food and Drug Administration (FDA). On the other hand, invasive technique, DBS, is also an FDA-approved treatment and, in the late 1980s, it began to emerge as a life-changing therapy for patients with involuntary movement disorders. (Kandel, et al., 2000)

NON-INVASIVE BRAIN STIMULATION

Transcranial magnetic stimulation

TMS is a neuromodulation technique that uses large transient magnetic fields to induce focal electrical fields in a specific brain area, and the availability of sophisticated equipment has made it possible to employ repetitive TMS (rTMS). The effects of rTMS vary depending on the shape of the coil (figure of eight, H coil, double cone coil), pacing pattern (high frequency, low frequency, theta-burst), and stimulation site. In fact, TMS is considered as a tool with great therapeutic potential because it is safe and the risk of severe negative side effects upon application is very low. Zhou, Y., et al. (2013).

Mechanism of action

TMS induces short pulses of intracranial electrical current and is applied in several ways: as single pulse, as paired pulse to the same or different brain areas, or as rTMS. Single-pulse stimulus depolarizes neurons; however, rTMS can induce changes in excitability of the cerebral cortex, locally as well as in neurons at areas far from the stimulation site, along functional anatomical connections. Although underlying mechanisms of the therapeutic outcomes of rTMS application have not been fully elucidated, rTMS can induce changes in cerebral blood flow,- Nestler, E. J., et al. (2002). oxygen consumption, cortical activity, and release of neurotransmitters. Therefore, it has been argued that these functional changes might be associated with positive clinical results. Stahl, S. M. (2000)

TMS application to alleviate the symptoms of neurological disorders

For effective TMS application, adjustments in both spatial and temporal parameters are essential. In literature, for the determination of spatial location of a target in brain, 52% of the studies have used magnetic resonance imaging, 27% scalp measurement, 15% functional magnetic resonance imaging, and 6% hotspot targeting.[2] Similarly, temporal parameters, which include stimulation frequency, number of pulses per trial, and interval duration between each stimulus, are also diverse. For stimulation frequency, few studies have used low-frequency stimulation of 1 Hz and most studies have applied a high-frequency stimulation ranging from 5 Hz (in 14%), 10–19 Hz (in 67%), to more than 20 Hz (in 20%). The stimulus interval time varied from 300 ms to 37,400 ms, and the number of pulses administered in each trial was <10; however, some studies applied more than 20 pulses. Additionally, combining rTMS with concurrent behavioral interventions in some neurological disorders has turned out to be more effective. Stahl, S. M. (2000).

Transcranial direct current stimulation

tDCS is the most used form of electrical stimulation. In comparison with rTMS, tDCS is not as powerful and generates weak stimulus; however, it is relatively easy to use and transport, lot less expensive, and it has low incidence of side effects. The effect of tDCS varies according to the type of current (direct, alternating, pulsed, random noise), polarity (anodal or cathodal), current intensity, and stimulation site.

Mechanism of action

tDCS modulates neural activity by delivering low-amplitude electrical current through electrodes and therefore causes a change in the cortical excitability. An anodal tDCS stimulation enhances excitatory synaptic transmission by stimulating glutamate transmission and suppressing gamma-aminobutyric acid (GABA) transmission and that the change in the balance between glutamate and GABA activities leads to modification in functional connectivity between brain regions. The effect of anodal tDCS stimulation also extends to other brain areas through decrease/increase in axonal release of monoamine transmitters, such as dopamine. In addition, an anodal tDCS stimulation has been shown to cause induction in long-term potentiation (LTP), increase in cAMP accumulation and mRNA expression, which are kinds of biological activities that facilitate the processing of cognitive functions. Zhou, Y., et al. (2013).

Invasive Brain Stimulation

Deep brain stimulation

DBS treatment implies passing electric current into the subcortical nuclei of the brain through surgically implanted electrodes. In contrast to rTMS and tDCS, DBS treatment in some of the brain nuclei has been shown to produce severe side effects.

Mechanism of action

Although how DBS produces improvements remains not well understood, it has been shown that DBS treatment changes brain activity in a controlled way. The effects of DBS tend to cause excitation in neighboring axons, improvement in microvascular integrity, increase in local cerebral blood flow, and stimulation in astrocytes to release calcium, which can further lead to the release of glutamate and adenosine. In addition, there is evidence that DBS can induce local and possibly distal proliferation of neurons. Nevertheless, from a neurophysiological point of view, the "disruption hypothesis" appears to be increasingly accepted. According to this hypothesis, DBS dissociates the input and output signals and causes a disruption in the anomalous flow of information.

Pharmacological Interventions

Pharmacological Interventions in Neurodegenerative Diseases

Pharmacological interventions in neurodegenerative diseases are designed to alleviate symptoms, slow disease progression, and improve the quality of life for patients. These interventions target various aspects of disease pathology, including neurotransmitter imbalances, neuroinflammation, oxidative stress, and protein misfolding. In Alzheimer's disease (AD), enhancing cholinergic neurotransmission is a primary strategy. Acetylcholinesterase inhibitors (AChEIs), such as donepezil, rivastigmine, and galantamine, increase acetylcholine levels in the brain by inhibiting the enzyme that breaks down this neurotransmitter. These drugs can improve cognitive function and delay the progression of symptoms in patients with mild to moderate AD. Memantine, an NMDA receptor antagonist, is used to moderate the effects of glutamate excitotoxicity, which is believed to contribute to neuronal damage in AD. By modulating NMDA receptor activity, memantine helps protect neurons from excessive glutamate signaling and can improve cognitive and functional outcomes in moderate to severe AD. (Holsboer, F. (2000).

In Parkinson's disease (PD), pharmacological treatments primarily focus on replenishing dopamine levels and managing motor symptoms. Levodopa, the precursor to dopamine, is the most effective treatment for PD and is often combined with carbidopa, which inhibits the peripheral breakdown of levodopa, allowing more of it to reach the brain. Dopamine agonists, such as pramipexole and ropinirole, directly stimulate dopamine receptors and are used as monotherapy in early-stage PD or in combination with levodopa in later stages. Monoamine oxidase B (MAO-B) inhibitors, such as selegiline and rasagiline, inhibit the breakdown of dopamine in the brain, thereby increasing its availability. Catechol-O-methyltransferase (COMT) inhibitors, such as entacapone and tolcapone, also prolong the effect of levodopa by inhibiting its metabolism. These pharmacological interventions help manage motor symptoms, although long-term use can lead to complications such as motor fluctuations and dyskinesias.

Pharmacological approaches in multiple sclerosis (MS) target the inflammatory and immune processes underlying the disease. Disease-modifying therapies (DMTs) are the cornerstone of MS treatment and include injectable agents such as interferon beta and glatiramer acetate, oral agents like fingolimod, dimethyl fumarate, and teriflunomide, and infusion therapies such as natalizumab and ocrelizumab. These drugs modulate the immune system to reduce the frequency and severity of relapses, slow the progression of disability, and limit the development of new lesions in the central nervous system. For symptomatic management, spasticity can be treated with muscle relaxants like baclofen and tizanidine, while neuropathic pain may be managed with antiepileptic drugs such as gabapentin and pregabalin. In amyotrophic lateral sclerosis (ALS), riluzole and edaravone are the only FDA-approved drugs that have shown some efficacy in slowing disease progression. Riluzole reduces glutamate excitotoxicity, while edaravone acts as an antioxidant to reduce oxidative stress. Symptomatic treatments, such as antispasmodics for spasticity and non-invasive ventilation for respiratory failure, are also important components of ALS management. (Holsboer, F. (2000).



Figure 4: Oxidative stress and Neurological disorders

In conclusion, the exploration of neurochemical aspects of mental health and neurological diseases highlights the complex interplay between neurotransmitters, neuroinflammation, and oxidative stress in the pathogenesis and progression of these disorders. Pharmacological interventions, while varied and often disease-specific, share common goals of symptom alleviation, disease modification, and improvement in quality of life. Alzheimer's disease (AD), for instance, benefits from cholinesterase inhibitors that boost cholinergic function and NMDA receptor antagonists that mitigate glutamate excitotoxicity, offering symptomatic relief and functional improvements. Parkinson's disease (PD) therapies focus on dopaminergic strategies, utilizing levodopa in combination with carbidopa to enhance dopamine synthesis and minimize peripheral metabolism, alongside dopamine agonists, MAO-B inhibitors, and COMT inhibitors to prolong dopaminergic activity and manage motor symptoms. Multiple sclerosis (MS) treatments emphasize immune modulation, with a variety of disease-modifying therapies (DMTs) such as interferon beta, glatiramer acetate, fingolimod, and natalizumab aimed at reducing relapse rates, slowing disability progression, and preventing new lesion formation. Symptomatic management in MS addresses spasticity with muscle relaxants like baclofen and neuropathic pain with antiepileptic drugs like gabapentin. In amyotrophic lateral sclerosis (ALS), the limited pharmacological arsenal includes riluzole, which reduces glutamate-mediated excitotoxicity, and edaravone, an antioxidant that mitigates oxidative stress, alongside supportive treatments for spasticity and respiratory failure. The intricate mechanisms of neuroinflammation, involving microglial and astrocytic activation and the release of pro-inflammatory cytokines, are pivotal in the pathology of neurodegenerative diseases, often exacerbating neuronal damage and contributing to disease progression. Understanding these processes has led to therapeutic approaches aimed at modulating the immune response and protecting neurons. The future of neurodegenerative disease treatment lies in the continued development of targeted therapies that address the underlying neurochemical and molecular mechanisms, offering hope for more effective disease management and improved patient outcomes. While current pharmacological interventions provide critical benefits, ongoing research and advancements in our understanding of neurochemistry hold the promise of novel treatments that can more precisely and effectively combat these debilitating conditions. Thus, the convergence of neurochemical insights and therapeutic innovations is poised to transform the landscape of mental health and neurological disease management, paving the way for enhanced therapeutic strategies and better quality of life for affected individuals. (Holsboer, F. (2000).

Recommendations

1. Integration of Multimodal Approaches:

Recommendation: Integrate neurochemical insights with genetic, imaging, and clinical data to develop a more comprehensive understanding of mental health and neurological disorders, Rationale: Combining various data types can enhance the accuracy of diagnoses and tailor treatments to individual patients more effectively.

2. Focus on Early Detection and Prevention:

Recommendation: Develop and implement screening tools for early detection of neurochemical imbalances and their associated disorders, Rationale: Early intervention can improve treatment outcomes and potentially prevent the progression of neurodegenerative and psychiatric conditions.

3. Explore Novel Therapeutic Targets:

Recommendation: Investigate and validate new neurochemical targets for drug development, including those related to neurotransmitter systems and neuroinflammation, Rationale: Targeting specific neurochemical pathways can lead to the development of more effective and less side-effect-prone therapies.

4. Personalize Treatment Plans:

Recommendation: Utilize personalized medicine approaches by considering individual differences in neurochemical profiles, genetics, and response to previous treatments, Rationale: Personalized treatments can enhance efficacy and reduce adverse effects by aligning therapies with individual biological and clinical characteristics.

5. Enhance Research on Neuroplasticity:

Recommendation: Invest in research exploring the role of neuroplasticity in mental health and neurological diseases, including how neurochemical changes affect brain plasticity, Rationale: Understanding neuroplasticity can offer new insights into the mechanisms underlying these disorders and identify potential avenues for therapeutic intervention.

6. Promote Interdisciplinary Collaboration:

Recommendation: Encourage collaboration among neurobiologists, pharmacologists, psychiatrists, and neurologists to foster a holistic approach to studying and treating neurochemical disorders, Rationale: Interdisciplinary efforts can bridge gaps between basic research and clinical practice, leading to more integrated and effective treatment strategies.

7. Expand Access to Treatments:

Recommendation: Work towards improving access to cutting-edge neurochemical therapies and interventions for underserved populations. Rationale: Broader access to advanced treatments can help address disparities in mental health and neurological care, improving outcomes for diverse patient groups.

References

1. Kandel, E. R., Schwartz, J. H., & Jessell, T. M. (2000). Principles of Neural Science. McGraw-Hill.
2. Zhou, Y., et al. (2013). The role of neurochemistry in mental health and neurological diseases. Neurobiology of Disease, 50, 1-10.
3. Stahl, S. M. (2000). Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press.
4. Nestler, E. J., et al. (2002). The neurobiology of depression. Neuron, 34(1), 13-25.
5. Hyman, S. E. (2009). The neurobiology of addiction: implications for voluntary control of behavior. American Journal of Psychiatry, 166(9), 942-944.
6. Reeves, A. J., et al. (2002). Neurochemical changes in Alzheimer's disease: implications for pathogenesis and treatment. Journal of Neurology, Neurosurgery, and Psychiatry, 73(5), 525-530.
7. Stahl, S. M. (2000). Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press.
8. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry, 122(5), 509-522.
9. Nuss, P. (2015). Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatric Disease and Treatment, 11, 165-175.
10. Coppen, A. (1967). The biochemistry of affective disorders. British Journal of Psychiatry, 113(504), 1237-1264)
11. Grace, A. A. (2016). Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nature Reviews Neuroscience, 17(8), 524-532.
12. Holsboer, F. (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 23(5), 477-501.
13. Berridge, K. C., & Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Research Reviews, 28(3), 309-369.
14. Savitz, J., et al. (2009). The Kynurenine Pathway: a link between immunity and depression. Molecular Psychiatry, 14(4), 336-353.
15. Fleckenstein, A. E., et al. (2007). New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology, 47, 681-698.
16. Miller, A. H., et al. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65(9), 732-741.
17. Perry, V. H., et al. (2010). The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective. Nature Reviews Neuroscience, 11(3), 189-198.
18. 2. Peng, Z.D., Lisanby, S.H. & Peterchev, A.V., 2013. Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. Brain Stimulation, 6(1), pp.1-13.
19. Kobayashi, M. & Pascual-Leone, A., 2003. Transcranial magnetic stimulation in neurology. Lancet Neurology, 2(3), pp.145-156.
20. Klomjai, W., Katz, R. & Lackmy-Vallée, A., 2015. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Annals of Physical and Rehabilitation Medicine, 58(4), pp.208-213.

21. Richieri, R., Boyer, L., Padovani, R., et al., 2012. Equivalent brain SPECT perfusion changes underlying therapeutic efficiency in pharmacoresistant depression using either high-frequency left or low-frequency right prefrontal rTMS. Progress in Neuropsychopharmacology and Biological Psychiatry, 39(2), pp.364-370.
22. Yamanaka, K., Tomioka, H., Kawasaki, S., et al., 2014. Effect of parietal transcranial magnetic stimulation on spatial working memory in healthy elderly persons - comparison of near infrared spectroscopy for young and elderly. PLoS One, 9(7), e102306.
23. Lenz, M., Galanis, C., Muller-Dahlhaus, F., et al., 2016. Repetitive magnetic stimulation induces plasticity of inhibitory synapses. Nature Communications, 7, 10020.
24. Su, L., Cai, Y., Xu, Y., Dutt, A., Shi, S. & Bramon, E., 2014. Cerebral metabolism in major depressive disorder: a voxel-based meta-analysis of positron emission tomography studies. BMC Psychiatry, 14, 321.
25. Beynel, L., Appelbaum, L.G., Luber, B., et al., 2019. Effects of online repetitive transcranial magnetic stimulation (rTMS) on cognitive processing: A meta-analysis and recommendations for future studies. Neuroscience and Biobehavioral Reviews, 107, pp.47-58.
26. Sathappan, A.V., Luber, B.M. & Lisanby, S.H., 2019. The Dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions. Progress in Neuropsychopharmacology and Biological Psychiatry, 89, pp.347-360.
27. Khedr, E.M., Rothwell, J.C., Shawky, O.A., Ahmed, M.A. & Hamdy, A., 2006. Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson's disease. Movement Disorders, 21(12), pp.2201-2205.
28. Mally, J., Farkas, R., Tothfalusi, L. & Stone, T.W., 2004. Long-term follow-up study with repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease. Brain Research Bulletin, 64(3), pp.259-263.
29. Pascual-Leone, A., Valls-Sole, J., Wassermann, E.M. & Hallett, M., 1994. Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain, 117(Pt 4), pp.847-858.
30. Yang, C., Guo, Z., Peng, H., et al., 2018. Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta-analysis. Brain and Behavior, 8(11), e01132.
31. Yokoe, M., Mano, T., Maruo, T., et al., 2018. The optimal stimulation site for high-frequency repetitive transcranial magnetic stimulation in Parkinson's disease: A double-blind crossover pilot study. Journal of Clinical Neuroscience, 47, pp.72-78.
32. González-García, N., Armony, J.L., Soto, J., Trejo, D., Alegría, M.A. & Drucker-Colín, R., 2011. Effects of rTMS on Parkinson’s disease: a longitudinal fMRI study. Journal of Neurology, 258(7), pp.1268-1280.
33. Alagona, G., Bella, R., Ferri, R., et al., 2001. Transcranial magnetic stimulation in Alzheimer disease: motor cortex excitability and cognitive severity. Neuroscience Letters, 314(1–2), pp.57-60.
34. Julkunen, P., Jauhiainen, A.M., Westeren-Punnonen, S., et al., 2008. Navigated TMS combined with EEG in mild cognitive impairment and Alzheimer's disease: a pilot study. Journal of Neuroscience Methods, 172(2), pp.270-276.
35. Bentwich, J., Dobronevsky, E., Aichenbaum, S., et al., 2011. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the

treatment of Alzheimer's disease: a proof of concept study. Journal of Neural Transmission (Vienna), 118(3), pp.463-471.

36. Zhao, J., Li, Z., Cong, Y., et al., 2017. Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer's disease patients. Oncotarget, 8(20), pp.33864-33871.
37. Nguyen, J.P., Suarez, A., Kemoun, G., et al., 2017. Repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease. Neurophysiology Clinical, 47(1), pp.47-53.
38. Alcala-Lozano, R., Morelos-Santana, E., Cortes-Sotres, J.F., Garza-Villarreal, E.A., Sosa-Ortiz, A.L. & Gonzalez-Olvera, J.J., 2018. Similar clinical improvement and maintenance after rTMS at 5 Hz using a simple vs. complex protocol in Alzheimer's disease. Brain Stimulation, 11(3), pp.625-627.
39. Lee, J., Choi, B.H., Oh, E., Sohn, E.H. & Lee, A.Y., 2016. Treatment of Alzheimer's disease with repetitive transcranial magnetic stimulation combined with cognitive training: a prospective, randomized, double-blind, placebo-controlled study. Journal of Clinical Neurology, 12(1), pp.57-64.
40. Rabey, J.M., Dobronevsky, E., Aichenbaum, S., Gonen, O., Marton, R.G. & Khaigrekht, M., 2013. Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study. Journal of Neural Transmission (Vienna), 120(5), pp.813-819.
41. Chou, Y.H., Ton That, V. & Sundman, M., 2020. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 86, pp.1-10.
42. Liao, X., Li, G., Wang, A., et al., 2015. Repetitive transcranial magnetic stimulation as an alternative therapy for cognitive impairment in Alzheimer's disease: a meta-analysis. Journal of Alzheimer's Disease, 48(2), pp.463-472.
43. Zhang, N., Xing, M., Wang, Y., Tao, H. & Cheng, Y., 2015. Repetitive transcranial magnetic stimulation enhances spatial learning and synaptic plasticity via the VEGF and BDNF-NMDAR pathways in a rat model of vascular dementia. Neuroscience, 311, pp.284-291.
44. Yang, H.Y., Liu, Y., Xie, J.C., Liu, N.N. & Tian, X., 2015. Effects of repetitive transcranial magnetic stimulation on synaptic plasticity and apoptosis in vascular dementia rats. Behavioral Brain Research, 281, pp.149-155.
45. Zhang, X.Q., Li, L., Huo, J.T., Cheng, M. & Li, L.H., 2018. Effects of repetitive transcranial magnetic stimulation on cognitive function and cholinergic activity in the rat hippocampus after vascular dementia. Neural Regeneration Research, 13(8), pp.1384-1389.
46. Rektorova, I., Megova, M., Bares, M. & Rektor, I., 2005. Cognitive functioning after repetitive transcranial magnetic stimulation in patients with cerebrovascular disease without dementia: a pilot study of seven patients. Journal of Neurological.